LITFULO, a JAK3 and TEC family kinase inhibitor already approved for severe alopecia areata, showed a safety profile consistent with prior alopecia areata data, with no new signals reported
doi:10.1016/j.mce.2013.09.025
AOD-9604 is not a substitute for GLP-1 agonists in clinical obesity
Those results dwarf what any single peptide, supplement, or lifestyle modification achieves in isolation
The dose is deliberately high compared to classical peptides (5-10 mg for GLP-1 analogues, 2-5 mg for short regeneratives) because documented GHK-Cu protocols use larger quantities in trichological and cutaneous research (1-3 mg per injection, concentrated topical applications)
Local Targeting for Injuries Injections can also be administered locally near the site of injury , concentrating the peptides effects